Results for tag: "Bavencio"

Bavencio is a drug used to treat advanced lung cancer. It is a type of immunotherapy, which works by helping the body’s immune system recognize and attack cancer cells. Bavencio is approved for use in combination with other drugs to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It is also approved for use in combination with other drugs to treat metastatic Merkel cell carcinoma (MCC). Bavencio is a monoclonal antibody, which means it is a type of protein that binds to a specific target on cancer cells. It works by blocking the activity of a protein called PD-L1, which helps cancer cells hide from the immune system. By blocking PD-L1, Bavencio helps the immune system recognize and attack cancer cells. The Bavencio market is made up of a variety of companies, including Merck, Pfizer, AstraZeneca, and Bristol-Myers Squibb. These companies are involved in the research, development, and marketing of Bavencio and other drugs used to treat lung cancer. They are also involved in the production and distribution of Bavencio and other drugs used to treat lung cancer. Show Less Read more